Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages 1147-1157

  Goto, Koichi ^a   Ohe, Yuichiro ^b   Shibata, Taro ^c   Seto, Takashi ^d   Takahashi, Toshiaki ^e   Nakagawa, Kazuhiko ^f   Tanaka, Hiroshi ^g   Takeda, Koji ^h   Nishio, Makoto ⁱ   Mori, Kiyoshi ^j   Satouchi, Miyako ^k   Hida, Toyoaki ^l   Yoshimura, Naruo ^m   Kozuki, Toshiyuki ⁿ   Imamura, Fumio ^o   Kiura, Katsuyuki ^p   Okamoto, Hiroaki ^q   Sawa, Toshiyuki ^r   Tamura, Tomohide ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NIIGATA CANCER CENTER HOSPITAL   (Japan)

^h OSAKA CITY GENERAL HOSPITAL   (Japan)

ⁱ CANCER INSTITUTE HOSPITAL   (Japan)

^j TOCHIGI CANCER CENTER   (Japan)

^k HYOGO CANCER CENTER   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^o OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^p OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^q YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^r Gifu Municipal Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; TOPOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHEMOSENSITIVITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TOPOTECAN;

EID: 84995934886     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30104-8     Document Type: Article

References (34)

1. 1 Hansen, HH, Management of small-cell cancer of the lung. Lancet 339 (1992), 846–849.
2. 2 Ardizzoni, A, Hansen, H, Dombernowsky, P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (1997), 2090–2096.
3. 3 Giaccone, G, Donadio, M, Bonardi, G, Testore, F, Calciati, A, Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 6 (1988), 1264–1270.
4. 4 Kim, YH, Goto, K, Yoh, K, et al. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 113 (2008), 2518–2523.
5. 5 Postmus, PE, Berendsen, HH, van Zandwijk, N, Splinter, TA, Burghouts, JT, Bakker, W, Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23 (1987), 1409–1411.
6. 6 O'Brien, ME, Ciuleanu, TE, Tsekov, H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (2006), 5441–5447.
7. 7 von Pawel, J, Schiller, JH, Shepherd, FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999), 658–667.
8. 8 Einhorn, LH, Pennington, K, McClean, J, Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 17 (1990), 32–35.
9. 9 Johnson, DH, Greco, FA, Strupp, J, Hande, KR, Hainsworth, JD, Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8 (1990), 1613–1617.
10. 10 Le Chevalier, T, Ibrahim, N, Chomy, P, et al. A phase II study of irinotecan in patients with small cell lung cancer progressing after initial response to first-line chemotherapy. Proc Am Soc Clin Oncol, 16, 1997, 450a.
11. 11 Masuda, N, Fukuoka, M, Kusunoki, Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 (1992), 1225–1229.
12. 12 Kubota, K, Nishiwaki, Y, Kakinuma, R, et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15 (1997), 292–296.
13. 13 Masuda, N, Fukuoka, M, Matsui, K, et al. Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 65 (1990), 2635–2640.
14. 14 Masuda, N, Matsui, K, Negoro, S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16 (1998), 3329–3334.
15. 15 Sekine, I, Nishiwaki, Y, Kakinuma, R, et al. Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br J Cancer 88 (2003), 808–813.
16. 16 Vasey, PA, Kaye, SB, Combined inhibition of topoisomerases I and II—is this a worthwhile/feasible strategy?. Br J Cancer 76 (1997), 1395–1397.
17. 17 Goto, K, Sekine, I, Nishiwaki, Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 91 (2004), 659–665.
18. 18 Pocock, SJ, Simon, R, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975), 103–115.
19. 19 Eckardt, JR, von Pawel, J, Pujol, JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25 (2007), 2086–2092.
20. 20 von Pawel, J, Jotte, R, Spigel, DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32 (2014), 4012–4019.
21. 21 Schoenfeld, DA, Richter, JR, Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38 (1982), 163–170.
22. 22 Lan, KKG, DeMets, DL, Discrete sequential boundaries for clinical trials. Biometrika 70 (1983), 659–663.
23. 23 Lowenbraun, S, Bartolucci, A, Smalley, RV, Lynn, M, Krauss, S, Durant, JR, The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44 (1979), 406–413.
24. 24 Giaccone, G, Ferrati, P, Donadio, M, Testore, F, Calciati, A, Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 23 (1987), 1697–1699.
25. 25 Noda, K, Nishiwaki, Y, Kawahara, M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002), 85–91.
26. 26 Lara, PN Jr, Natale, R, Crowley, J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27 (2009), 2530–2535.
27. 27 Hanna, N, Bunn, PA Jr, Langer, C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006), 2038–2043.
28. 28 Murray, N, Shah, A, Osoba, D, et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9 (1991), 1632–1638.
29. 29 Furuse, K, Fukuoka, M, Nishiwaki, Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 16 (1998), 2126–2132.
30. 30 Murray, N, Livingston, RB, Shepherd, FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17 (1999), 2300–2308.
31. 31 Jotte, R, Conkling, P, Reynolds, C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29 (2011), 287–293.
32. 32 Huber, RM, Reck, M, Gosse, H, et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J 27 (2006), 1183–1189.
33. 33 Fields, SZ, Eckardt, JR, Zhang, L, Poulin, RK, Rose, G, Schiller, JH, Efficacy of reduced dose of IV topotecan in relapsed small cell lung cancer patients. Lung Cancer, 29(suppl 1), 2000, 10.
34. 34 Takeda, K, Negoro, S, Sawa, T, et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 4 (2003), 224–228.